Biggest News Aggregation in the World
📰 Durable Responses News

Page 2 - Durable Responses News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Durable Responses. Real-time updates on events, politics, business and more.

Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting

/PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies,...
United States Ghayasc Issa Sharon Klahre Michaela Metzger Division Of Cancer Medicine Company On Twitter

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
United States East Hanover Novartis Scemblix Isabella Zinck Jeff Legos Amy Wolf

Novartis Pharma AG: Novartis Scemblix, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial

Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-week
United States East Hanover Isabella Zinck Jeff Legos Amy Wolf Nicole Zinsli Somm

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia
United States East Hanover Novartis Scemblix Isabella Zinck Jeff Legos Thomas Hungerbuehler

Novartis Pharma AG: Novartis Scemblix demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix (asciminib) vs. Bosulif* (bosutinib) and lower discontinuation rate due to adverse
United States East Hanover Isabella Zinck Jeff Legos Thomas Hungerbuehler Floriana Riccio Furnari

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science